Evaluation and management of peripheral neuropathy in diabetic patients with cancer.
Recently, chemotherapy-induced peripheral neuropathy has received a great deal of attention. However, the interaction of diabetic neuropathy with potentially neurotoxic chemotherapy is far less understood. The incidence of type II diabetes has risen exponentially in the past two decades. In concert with the rise in type II diabetes, the number of individuals with diabetes who need chemotherapy for cancer also is expected to increase. Diabetic neuropathy and the neurotoxic effects of chemotherapy have a significant potential to cause functional disability. Diabetics may be most at risk for the effects of neurotoxic agents on peripheral nerve functioning, in addition to the other effects induced by chemotherapeutic agents. The purpose of this article is to review the evaluation, management, and clinical implications of peripheral neuropathy in patients with cancer and diabetes.
Visovsky
Constance
C
Nursing Program, University of Nebraska Medical Center, Omaha, NE, USA. cvisovsky@unmc.edu
Meyer
Rachel R
RR
Roller
Jeffre
J
Poppas
Megan
M
D000970:Antineoplastic Agents / Q000009:adverse effects*; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology; D003929:Diabetic Neuropathies / Q000150:complications*; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009460:Neurologic Examination / Q000379:methods / Q000451:nursing; D009730:Nursing Assessment / Q000379:methods*; D009859:Oncology Nursing / Q000379:methods*; D010353:Patient Education as Topic; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D017751:Safety Management; D012720:Severity of Illness Index
D000970:Antineoplastic Agents